Genfarma - Technology Transfer Platform
Connecting Global Biotechnology with Vietnam’s Healthcare
In the global biopharmaceutical industry, Technology Transfer (TT) is the most critical and technically demanding discipline: it requires absorbing advanced scientific know-how from international originators (Sending Un its - SUs) and reproducing it locally with absolute molecular equivalence, purity, biological potency, and sterility assurance.
In Vietnam, WE – GENFARMA, Receiving Unit (RU) possess the cleanroom infrastructure, analytical rigor, risk governance, and multidisciplinary human capital required to connect global biotechnology innovation with domestic cGMP manufacturing excellence - delivering internationally compliant, life-saving biotherapeutics to hospitals and patients across Vietnam.
|
Global Sending Unit (SU)
INTERNACIONAL TECHNOLOGY LICENSORS
|
Receiving Unit (RU) – Vietnam
GENFARMA – HIGH-TECH BIOLOGICS HUB
|
Hospitals & Benefitting Patients
DIRECT CLINICAL BENEFICIARIES IN VIETNAM
|
|

|


I. Vaccine & Biologic Transfer Readiness
§ Existing manufacturing foundation: solution preparation, vial filling, lyophilization and packaging, supported by QC and temperature-controlled storage
§ Vaccine transfer opportunities: evaluate local fill & finish of selected partner vaccine bulks in compatible vial formats
§ Biologic transfer opportunities: evaluate formulation and fill & finish of compatible liquid or lyophilized products
§ Product-specific assessment: confirm containment, formulation compatibility, analytical methods, cold-chain requirements and stability
§ Commercial readiness: define facility adaptations, qualification, process validation and regulatory approvals with each technology partner
II. Master Portfolio Executive Dashboard
Projects are managed according to an implementation model that includes product-specific GAP and feasibility assessment; agreed transfer scope & applicable regulatory approvals; readiness preparation; execution of Process Performance Qualification (PPQ); and handover to commercial production.
Genfarma concurrently executes 27 complex biopharmaceutical transfer projects and look forward for further collaboration with more SUs worldwide to further contributing for a better Vietnam’s healthcare.
|
Genfarma Live Technology Transfer Pipeline:
|
|
|
Total: 27
|
Active: 26 (96.3%)
|
Completed: 01 (3.7%)
|
On Hold: 0 (0%)
|
|
Interactive Live Technology Transfer Pipeline:
|
|
|
07
mAbs
|
11
Recombinant Proteins
|
|
04
Peptides
|
|
05
Polysaccharides
|
| |
|
|
|
|
|
|
Grounded in PDA Technical Report No. 65 (Technology Transfer) and WHO guidelines, Genfarma Technology transfer is governed as a rigorous 6-Stage lifecycle controlled by formal Go/No-Go quality gates.
|
Lifecycle Stage
|
Title
|
Technical Objective
|
Decision Gate
|
Live Project Count
|
|
STAGE 01
|
1. Initiation (RU)
|
Technical feasibility & RU site readiness evaluation
|
Gate 1 (Go / No-Go)
|
23 Active (85.2%)
|
|
STAGE 02
|
2. Planning (RU)
|
Master project plan, risk matrix & TT Protocol approval
|
Gate 2 (Go / No-Go)
|
0 Active (0%)
|
|
STAGE 03
|
3. Knowledge Transfer
|
SU-to-RU dossier handover, CPPs/CQAs & technical training
|
Gate 3 (Go / No-Go)
|
0 Active (0%)
|
|
STAGE 04
|
4. Readiness (RU)
|
Cleanroom qualification, analytical transfer & pre-PPQ readiness.
|
Gate 4 (Go / No-Go)
|
02 Active (7.4%)
|
|
STAGE 05
|
5. Execution (PPQ)
|
Commercial-scale PPQ validation batches & comparability.
|
Gate 5 (Go / No-Go)
|
01 Active (3.7%)
|
|
STAGE 06
|
6. Handover (RU)
|
Routine cGMP commercial manufacturing & national supply.
|
Milestone / Release
|
01 Completed (3.7%)
|
|
Product
|
Therapeutic Effect & Mechanism
|
Benefiting Clinical Area
|
|
Nimotuzumab - Humanized Monoclonal Antibody
(anti-EGFR mAb)
|
Selectively binds to the human epidermal growth factor receptor (EGFR) with intermediate affinity, inhibiting tumor cell proliferation and angiogenesis with a benign cutaneous safety profile.
|
Oncology (Advanced head & neck squamous cell carcinoma, high-grade adult and pediatric astrocytoma / glioma, esophageal cancer)
|
|
III.Strategic Governance Pillars for Multi-Product Biopharmaceutical Complexity
Genfarma has developed capabilities and competitive strengths in receiving, developing, and implementing advanced biotechnology and biopharmaceutical projects under full cGMP compliance.

4 Integrated Pillar
|
1- Quality Risk Management & Analysis
Science-based biological risk control across every critical process parameter
Ø ICH Q9(R1) Governance
Ø Robust Supplier Qualification
Ø FMEA & CPP Control
Ø Lifecycle Risk Verification
|
2- Facility Engineering & Infrastructure
Advanced aseptic fill and finish engineered for zero cross-contamination
Ø Dedicated biologics filling line
Ø Dedicated HVAC Segregation
Ø High production capacity
Ø Validated Clean CIP/SIP Skids
|
3- SU & RU Communication & Training Pillars
Direct scientific immersion between global SUs and Genfarma specialists
Ø Bilateral SU-RU Governance
Ø Licensor Facility Immersion
Ø On-site Licensor Shadowing
Ø Collaborative Gate Sign-Offs
|
4- Regulatory Harmonization Across Diverse SUs
Unifying multinational CTD dossiers into compliant national & global submissions
Ø Multinational CTD Unification
Ø Pharmacopeial Reconciliation
Ø WHO-GMP to EU-GMP Harmonization
Ø ICH Q5E Comparability
|
Sterile Productive Capacity & Aseptic Filling Suites
Powered by World-Class Fill and Finish Platform & PUPSIT Technology in Segregated cGMP Cleanrooms — Built to Scale Global Biologics in Vietnam
Existing Fill & Finish Platform:

1. Solution preparation Capacity

§ Stainless steel vessels available for both SS vessels and SUS suitable for batch sizes from 20L to 1,000L
§ Heating/cooling jackets and magnetic mixing
§ Automated controls with audit trails and electronic records
2. Vial filling Capacity

§ Integrated vial washing, dehydrogenation, filling and stoppering
§ Suitable for vial from 2R ~ 100R
§ Product-specific filling parameters require transfer and validation
§ Automated controls support audit trails, electronic records/signatures and data integrity
§ Source specifications reference 21 CFR Part 11 and GAMP 5
3. Lyophilization Capacity

§ 3 lyophilizes with automatic vial loading and unloading
§ Automated control, monitoring and electronic records
§ A platform for transfer of product-specific freeze-drying cycles
4. Inspection & Packaging Capacity

§ Integrated automatic inspection, vacuum leak testing and labelling
§ Cartooning, online checkweighing and case packing
§ Automated controls support electronic records and data integrity: Product-specific inspection criteria and packaging formats form part of transfer
Storage & Cold Chain Infrastructure
Approximately 5,000 m³ of storage capacity is provided within designated areas maintained at defined temperature ranges, as appropriate for the controlled storage of packaging materials, excipients, active pharmaceutical ingredients (APIs), and finished products at their respective stages of operation.
.PNG)
Key Technological Differentiation
Pre-Use Post-Sterilization Integrity Testing (PUPSIT)
EU–GMP Annex 1
|
STEP 01
In-Situ Steam Sterilization
Automated SIP sterilization of 0.22 µm biofilters and single-use manifolds
|
STEP 02
Pre-Use Integrity Verification
Closed-barrier bubble-point & diffusive flow test prior to batch contact
|
STEP 03
Aseptic Product Filtration
Zero-touch sterile transfer into Grade A dosing needles with live ΔP tracking
|
STEP 04
Post-Use Dual Confirmation
Immediate post-batch integrity re-test confirming 100% membrane integrity
|
IV. Analytical Method Transfer (AMT) & Biopharmaceutical QC Platform
Powered by ICH-Compliant Analytical Method Transfer & 3-Platform Quality Control — Ensuring Molecular Comparability in Every Vial
Three Core Analytical Platforms . 30 Validated Testing Methods

|
Physicochemical Platform
14 Validated Testing Methods
§ MOLECULAR INTEGRITY
§ PURITY & PHYSICOCHEMICAL CQAs
§ SEC / RP-UHPLC CHROMATOGRAPHY
§ CAPILARY ELECTROPHORESIS
§ CCIT
|
Microbiological Platform
10 Validated Testing Methods
§ STERILITY ASSURANCE
§ RECOMBINANT ENDOTOXIN CONTROL (RFC)
§ BIOBURDEN & MICROBIAL ID
§ CONTINUOUS CLEANROOM EM
|
Biological Activity: InVivo & In Vitro Analytical Platform
6 Validated Testing Methods
§ MECHANISM OF ACTION
§ TARGET BINDING & FUNCTIONAL POTENCY
§ FLOW CYTOMETRY & IN VIVO/IN VITRO BIOASSAYS
§ CELL BANKING
|
COMING SOON § PLANNED AUTONOMOUS HUB
Autonomous Biological Activity Center:
In Vivo & In Vitro cGMP Testing Hub
Completed technical milestones . 3-phase pathway to 100% national sovereignty

V.Genfarma Core Technology Transfer Leadership & Expert Team
MULTIDISCIPLINARY BIOPHARMA LEADERSHIP
12 to 38+ years cGMP execution
|
1. OPERATION & TECHNICAL DIVISION DIRECTOR
__________________________________________________
MANUEL ENRIQUE MONTANE,
M.Sc. § 38+ YRS EXP
Key Focus: Biopharma Capital Investments
§ Plant Engineering & CQV
§ Blood Derivatives & Vaccine Tech Transfer
|
|
2. TECHNOLOGY TRANSFER LEAD
__________________________________________________
DAYMARA GONZÁLEZ FUENTES,
M.Sc. § 25+ YRS EXP
Key Focus: Cross-Border Biopharma Tech Transfer
§ ICH Q8/Q9/Q10 Quality by Design
§ CTD Regulatory Dossiers
|
|
3. PRODUCTION MANAGER
__________________________________________________
SERGIO CATÁ MURGUIDO,
M.Sc § 30+ YRS EXP
Key Focus: Leader in 20+ Internal & External Technology Transfer
§ Expert in Sterile Product Formulation, Filling & Packaging
|
|
|
|
|
|
|
|
4. QC MANAGER
________________________________________________
VLADIMIR PEÑA SÁNCHEZ,
M.Sc § 25+ YRS EXP
Key Focus: Biological QC Direction
§ Analytical Method Validation
§ Protein UF/DF & E&L Characterization
|
|
5. ENGINEERING MANAGER
________________________________________
VŨ QUANG HƯNG,
Eng. § 12+ YRS EXP
Key Focus: GMP Vaccine & Biopharma Plant Engineering
§ URS / P&ID Review
§ Aseptic Lines & Clean Utilities
|
|
6. QA MANAGER
____________________________________________________
NGUYEN CHI THANH,
M.Sc. § 28+ YRS EXP
Key Focus: 5 WHO-GMP Plant Certifications
§ Annex 1 QRM Compliance
§ International Tech Transfers
|